Zim Laboratories Limited (ZIMLAB) - Total Liabilities

Latest as of September 2025: Rs2.19 Billion INR ≈ $23.66 Million USD

Based on the latest financial reports, Zim Laboratories Limited (ZIMLAB) has total liabilities worth Rs2.19 Billion INR (≈ $23.66 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Zim Laboratories Limited liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Zim Laboratories Limited - Total Liabilities Trend (2013–2025)

This chart illustrates how Zim Laboratories Limited's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Zim Laboratories Limited balance sheet assets.

Zim Laboratories Limited Competitors by Total Liabilities

The table below lists competitors of Zim Laboratories Limited ranked by their total liabilities.

Company Country Total Liabilities
Wiener Privatbank SE
VI:WPB
Austria €311.71 Million
Nice D&B Co. Ltd
KQ:130580
Korea ₩22.48 Billion
Turbogen Chp
TA:TURB
Israel ILA30.57 Million
AI Financial Corporation
NASDAQ:AIFC
USA $66.46 Million
NWF GROUP PLC LS-25
F:NYY
Germany €182.60 Million
Endurance Gold Corp
V:EDG
Canada CA$687.19K
Bathurst Resources Ltd
AU:BRL
Australia AU$22.78 Million

Liability Composition Analysis (2013–2025)

This chart breaks down Zim Laboratories Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Zim Laboratories Limited balance sheet quality to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.42 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.87 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.47 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Zim Laboratories Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Zim Laboratories Limited (2013–2025)

The table below shows the annual total liabilities of Zim Laboratories Limited from 2013 to 2025.

Year Total Liabilities Change
2025-03-31 Rs2.20 Billion
≈ $23.77 Million
+5.63%
2024-03-31 Rs2.08 Billion
≈ $22.50 Million
+47.33%
2023-03-31 Rs1.41 Billion
≈ $15.27 Million
-14.88%
2022-03-31 Rs1.66 Billion
≈ $17.94 Million
+1.15%
2021-03-31 Rs1.64 Billion
≈ $17.74 Million
-4.34%
2020-03-31 Rs1.71 Billion
≈ $18.55 Million
-3.30%
2019-03-31 Rs1.77 Billion
≈ $19.18 Million
+9.68%
2018-03-31 Rs1.62 Billion
≈ $17.49 Million
+14.89%
2017-03-31 Rs1.41 Billion
≈ $15.22 Million
-10.83%
2016-03-31 Rs1.58 Billion
≈ $17.07 Million
-7.66%
2015-03-31 Rs1.71 Billion
≈ $18.48 Million
+15.82%
2014-03-31 Rs1.48 Billion
≈ $15.96 Million
+32.34%
2013-03-31 Rs1.11 Billion
≈ $12.06 Million
--

About Zim Laboratories Limited

NSE:ZIMLAB India Drug Manufacturers - Specialty & Generic
Market Cap
$71.42 Million
Rs6.60 Billion INR
Market Cap Rank
#20612 Global
#1132 in India
Share Price
Rs135.51
Change (1 day)
-1.75%
52-Week Range
Rs60.26 - Rs139.22
All Time High
Rs149.00
About

ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, granules, tablets, capsules, dry syrup, and oral thin films. The company offers the… Read more